Drug intelligence / Profile preview

99mTc-6

Development stage: Discontinued
Lead developer: Beijing Shihong Pharmaceutical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

99mTc-6 is a technetium-99m-based radiopharmaceutical diagnostic imaging agent developed by Beijing Shihong Pharmaceutical Co., Ltd. (also known as Beijing Shihong Pharmaceutical Center). It was designed for the detection and localization of neoplasms (tumors) using nuclear medicine imaging techniques. The agent utilizes the metastable nuclear isomer Technetium-99m, which emits gamma radiation that can be captured by Single Photon Emission Computed Tomography (SPECT) to provide non-invasive visualization of cancerous tissues. According to pipeline records from the developer, the development of this specific diagnostic candidate has been discontinued.

Beyond the preview

Go deeper on 99mTc-6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-6.

Explore the full profile